Discovery of 3-Quinazolin-4(3


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
09 Jul 2020
Historique:
received: 05 05 2020
accepted: 10 06 2020
entrez: 18 7 2020
pubmed: 18 7 2020
medline: 18 7 2020
Statut: epublish

Résumé

Phosphoinositide 3-kinases (PI3Ks) mediate a series of events related to cell growth, proliferation, survival, and differentiation. Overexpression of PI3Ks can lead to the dysregulation of cell homeostasis and cause tumorigenesis. In this study, rationally designed compounds were investigated as PI3Kα-selective inhibitors. Our efforts culminated in the discovery of a series of quinazolin-4(3

Identifiants

pubmed: 32676155
doi: 10.1021/acsmedchemlett.0c00239
pmc: PMC7357217
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1463-1469

Informations de copyright

Copyright © 2020 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

Nat Rev Cancer. 2015 Jan;15(1):7-24
pubmed: 25533673
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Bioorg Med Chem Lett. 2015 Nov 15;25(22):5155-62
pubmed: 26475521
Nature. 2012 Jun 20;486(7403):405-9
pubmed: 22722202
Cancer Discov. 2013 Jul;3(7):761-9
pubmed: 23619167
Curr Oncol Rep. 2019 Dec 11;21(12):110
pubmed: 31828441
Bioorg Med Chem. 2015 Dec 15;23(24):7765-76
pubmed: 26652969
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Drug Saf. 2019 Feb;42(2):247-262
pubmed: 30649751
Cancer Discov. 2019 Apr;9(4):482-491
pubmed: 30867161
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Clin Cancer Res. 2005 Apr 15;11(8):2875-8
pubmed: 15837735
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
ACS Med Chem Lett. 2016 Aug 03;7(10):919-923
pubmed: 27774129
Nat Rev Clin Oncol. 2018 May;15(5):273-291
pubmed: 29508857
J Med Chem. 2017 Mar 9;60(5):1662-1664
pubmed: 28234469
J Med Chem. 2016 Aug 11;59(15):7268-74
pubmed: 27427973
J Med Chem. 2011 Nov 24;54(22):7815-33
pubmed: 21985639
J Clin Oncol. 2018 May 1;36(13):1291-1299
pubmed: 29401002
Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8
pubmed: 23726034

Auteurs

Jiaqiang Dong (J)

Luoxin Pharmaceutical (Shanghai) Co., Ltd., Building 1 and First-Third Floors, Building 2, No. 85 Faladi Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 201203, China.

Jingjie Huang (J)

Domestic Discovery Service Unit, WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.

Ji Zhou (J)

Domestic Discovery Service Unit, WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.

Ye Tan (Y)

Domestic Discovery Service Unit, WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.

Jing Jin (J)

Domestic Discovery Service Unit, WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.

Xi Tan (X)

LTD, WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.

Bei Wang (B)

OIU, WuXi AppTec Co., Ltd., 1336 Wuzhong Avenue, Suzhou 215104, China.

Tao Yu (T)

Domestic Discovery Service Unit, WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.

Chengde Wu (C)

Domestic Discovery Service Unit, WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.

Shuhui Chen (S)

Domestic Discovery Service Unit, WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.

Tie-Lin Wang (TL)

Luoxin Pharmaceutical (Shanghai) Co., Ltd., Building 1 and First-Third Floors, Building 2, No. 85 Faladi Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 201203, China.

Classifications MeSH